FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783708539> ?p ?o ?g. }

• W2783708539 endingPage "858" @default.
• W2783708539 startingPage "850" @default.
• W2783708539 abstract "Purpose Treating solid tumors with cancer immunotherapy (CIT) can result in unconventional responses and overall survival (OS) benefits that are not adequately captured by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. We describe immune-modified RECIST (imRECIST) criteria, designed to better capture CIT responses. Patients and Methods Atezolizumab data from clinical trials in non–small-cell lung cancer, metastatic urothelial carcinoma, renal cell carcinoma, and melanoma were evaluated. Modifications to imRECIST versus RECIST v1.1 included allowance for best overall response after progressive disease (PD) and changes in PD definitions per new lesions (NLs) and nontarget lesions. imRECIST progression-free survival (PFS) did not count initial PD as an event if the subsequent scan showed disease control. OS was evaluated using conditional landmarks in patients whose PFS differed by imRECIST versus RECIST v1.1. Results The best overall response was 1% to 2% greater, the disease control rate was 8% to 13% greater, and the median PFS was 0.5 to 1.5 months longer per imRECIST versus RECIST v1.1. Extension of imRECIST PFS versus RECIST v1.1 PFS was associated with longer or similar OS. Patterns of progression analysis revealed that patients who developed NLs without target lesion (TL) progression had a similar or shorter OS compared with patients with RECIST v1.1 TL progression. Patients infrequently experienced a spike pattern (TLs increase, then decrease) but had longer OS than patients without TL reversion. Conclusion Evaluation of PFS and patterns of response and progression revealed that allowance for TL reversion from PD per imRECIST may better identify patients with OS benefit. Progression defined by the isolated appearance of NLs, however, is not associated with longer OS. These results may inform additional modifications to radiographic criteria (including imRECIST) to better reflect efficacy with CIT agents." @default.
• W2783708539 created "2018-01-26" @default.
• W2783708539 creator A5004935250 @default.
• W2783708539 creator A5015190461 @default.
• W2783708539 creator A5030914311 @default.
• W2783708539 creator A5038215538 @default.
• W2783708539 creator A5039801976 @default.
• W2783708539 creator A5040423968 @default.
• W2783708539 creator A5043917346 @default.
• W2783708539 creator A5047573588 @default.
• W2783708539 creator A5054656505 @default.
• W2783708539 creator A5066541232 @default.
• W2783708539 creator A5069854182 @default.
• W2783708539 creator A5072911394 @default.
• W2783708539 creator A5075259947 @default.
• W2783708539 creator A5080906910 @default.
• W2783708539 creator A5084967339 @default.
• W2783708539 creator A5086481435 @default.
• W2783708539 date "2018-03-20" @default.
• W2783708539 modified "2023-10-13" @default.
• W2783708539 title "Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy" @default.
• W2783708539 cites W1575257462 @default.
• W2783708539 cites W1971208896 @default.
• W2783708539 cites W1990675339 @default.
• W2783708539 cites W2019607817 @default.
• W2783708539 cites W2066671159 @default.
• W2783708539 cites W2075351817 @default.
• W2783708539 cites W2095267413 @default.
• W2783708539 cites W2097995306 @default.
• W2783708539 cites W2100158834 @default.
• W2783708539 cites W2101660499 @default.
• W2783708539 cites W2102143045 @default.
• W2783708539 cites W2102571808 @default.
• W2783708539 cites W2104347254 @default.
• W2783708539 cites W2110847259 @default.
• W2783708539 cites W2118982164 @default.
• W2783708539 cites W2122538591 @default.
• W2783708539 cites W2124427232 @default.
• W2783708539 cites W2124932867 @default.
• W2783708539 cites W2137264248 @default.
• W2783708539 cites W2148706732 @default.
• W2783708539 cites W2153778867 @default.
• W2783708539 cites W2156353875 @default.
• W2783708539 cites W2289712604 @default.
• W2783708539 cites W2293531514 @default.
• W2783708539 cites W2296049142 @default.
• W2783708539 cites W2554618897 @default.
• W2783708539 cites W2556154467 @default.
• W2783708539 cites W2567564314 @default.
• W2783708539 cites W2578528809 @default.
• W2783708539 cites W2588146309 @default.
• W2783708539 cites W2592144107 @default.
• W2783708539 cites W2601621622 @default.
• W2783708539 cites W2625684877 @default.
• W2783708539 cites W2626111365 @default.
• W2783708539 doi "https://doi.org/10.1200/jco.2017.75.1644" @default.
• W2783708539 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29341833" @default.
• W2783708539 hasPublicationYear "2018" @default.
• W2783708539 type Work @default.
• W2783708539 sameAs 2783708539 @default.
• W2783708539 citedByCount "266" @default.
• W2783708539 countsByYear W27837085392018 @default.
• W2783708539 countsByYear W27837085392019 @default.
• W2783708539 countsByYear W27837085392020 @default.
• W2783708539 countsByYear W27837085392021 @default.
• W2783708539 countsByYear W27837085392022 @default.
• W2783708539 countsByYear W27837085392023 @default.
• W2783708539 crossrefType "journal-article" @default.
• W2783708539 hasAuthorship W2783708539A5004935250 @default.
• W2783708539 hasAuthorship W2783708539A5015190461 @default.
• W2783708539 hasAuthorship W2783708539A5030914311 @default.
• W2783708539 hasAuthorship W2783708539A5038215538 @default.
• W2783708539 hasAuthorship W2783708539A5039801976 @default.
• W2783708539 hasAuthorship W2783708539A5040423968 @default.
• W2783708539 hasAuthorship W2783708539A5043917346 @default.
• W2783708539 hasAuthorship W2783708539A5047573588 @default.
• W2783708539 hasAuthorship W2783708539A5054656505 @default.
• W2783708539 hasAuthorship W2783708539A5066541232 @default.
• W2783708539 hasAuthorship W2783708539A5069854182 @default.
• W2783708539 hasAuthorship W2783708539A5072911394 @default.
• W2783708539 hasAuthorship W2783708539A5075259947 @default.
• W2783708539 hasAuthorship W2783708539A5080906910 @default.
• W2783708539 hasAuthorship W2783708539A5084967339 @default.
• W2783708539 hasAuthorship W2783708539A5086481435 @default.
• W2783708539 hasConcept C121608353 @default.
• W2783708539 hasConcept C126322002 @default.
• W2783708539 hasConcept C143998085 @default.
• W2783708539 hasConcept C2775949291 @default.
• W2783708539 hasConcept C2776256026 @default.
• W2783708539 hasConcept C2776694085 @default.
• W2783708539 hasConcept C2777472916 @default.
• W2783708539 hasConcept C2777701055 @default.
• W2783708539 hasConcept C2778822529 @default.
• W2783708539 hasConcept C2779134260 @default.
• W2783708539 hasConcept C2779984678 @default.
• W2783708539 hasConcept C2780030458 @default.
• W2783708539 hasConcept C2780400711 @default.
• W2783708539 hasConcept C2780739268 @default.

• next